作者
Miriam Saiz-Rodríguez, Carmen Belmonte, José Luis Caniego, Dora Koller, Pablo Zubiaur, Eduardo Bárcena, Daniel Romero-Palacián, Andy R Eugene, Dolores Ochoa, Francisco Abad-Santos
发表日期
2019/6/1
期刊
Clinical Therapeutics
卷号
41
期号
6
页码范围
1199-1212. e2
出版商
Elsevier
简介
Purpose
Clopidogrel is a thienopyridine prodrug that inhibits platelet aggregation. It is prescribed to prevent atherothrombotic and thromboembolic events in patients receiving a stent implant in carotid, vertebral, or cranial arteries. The influence of cytochrome P-450 (CYP) 2C19 on the response to clopidogrel has been widely studied; however, the effect of other genes involved in clopidogrel absorption and metabolism has not been established in this cohort of patients.
Methods
This observational retrospective study assessed the antiplatelet response and the prevalence of hemorrhagic or ischemic events after percutaneous neurointervention in clopidogrel-treated patients, related to 35 polymorphisms in the genes encoding the clopidogrel-metabolizing enzymes (CYP2C19, CYP1A2, CYP2B6, CYP2C9, CYP2C9, CYP3A4, CYP3A5, carboxylesterase-1 [CES1], and paraoxonase-1 [PON1]), P-glycoprotein transporter …
学术搜索中的文章
M Saiz-Rodríguez, C Belmonte, JL Caniego, D Koller… - Clinical Therapeutics, 2019